Open access
Sep 2026
A ketogenic enzyme HMGCS2 drives malignant progression in HER2-negative breast cancer via RAB23-mediated β-catenin/TCF signaling and mediates Apatinib resistance.
BACKGROUND 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) is the rate-limiting enzyme of ketogenesis. However, its role in breast cancer progression and drug resistance beyond metabolic regulation remains poorly understood. This study investigates the oncogenic function and resistance-promoting mechanism of HMGCS2...
Jing Wu, Mei Liu, Wei Li et al.
· Life Science · 0 citations